Publications

Anti-Nicotine Antibodies

• Keyler, D. et al. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab Dispos 33, 1056-1061 (2005).
• Beerli, R. et al. Isolation of human monoclonal antibodies by mammalian cell display. PNAS 105, 14336-14341 (2008).
• Carrera, M. et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem 12, 563-570 (2004).
• Kalnik, M. in Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes (ed Ivan D. Montoya) (Springer, 2016).
• Pentel, P. R. et al. A Nicotine Conjugate Vaccine Reduces Nicotine Distribution to Brain and Attenuates Its Behavioral and Cardiovascular Effects in Rats. Pharmacology Biochemistry and Behavior 65, 191-198 (2000).
• Pentel, P. & LeSage, M. New Directions in Nicotine Vaccine Design and Use. Adv Pharmacol. 69, 553-580 (2014)
• Raupach, T., H.J. Hoogsteder, P. & van Schayck, C. Nicotine Vaccines to Assist with Smoking Cessation: Current Status of Research. Drugs 2012 72, e1-e16 (2012).

Nicotine-degrading Enzymes

• Tang, H. et al. Systematic unraveling of the unsolved pathway of nicotine degradation in Pseudomonas. PLoS genetics 9, e1003923(2013).
• Xue, S., Schlosburg, J. E. & Janda, K. D. A New Strategy for Smoking Cessation: Characterization of a Bacterial Enzyme for the Degradation of Nicotine. J Am Chem Soc 137, 10136-10139 (2015).
• Janda, K. D., Kalnik, M. W., Thisted, T. Nicotine-degrading enzymes for treating nicotine addiction and nicotine poisoning. US Patent Application (2015). PCT/US2016/045109 WO/2017/023904.
• Tararina, M. A., Janda, K. D. & Allen, K. N. Structural Analysis Provides Mechanistic Insight into Nicotine Oxidoreductase from Pseudomonas putida. Biochemistry 55, 6595-6598, (2016).
• Xue, S. et al. An enzymatic advance in nicotine cessation therapy. Chemical Communications 54, 1686-1689 (2018).
• Pentel et al. The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats. (2018) BMC Biotechnology 18:46

Buerger’s Disease

• Piazza, G. & Olin, J. W. in Vascular Medicine: A Companion to Braunwald's Heart Disease (Second Edition)(eds Joshua A. Beckman & Joseph Loscalzo) 533-546 (W.B. Saunders, 2013).
• Puéchal, X. & Fiessinger, J. N. Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist. Rheumatology 46, 192-199, (2007).
• Cooper, L. T. et al. A Prospective, Case-control Study of Tobacco Dependence in Thromboangiitis Obliterans (Buerger’s Disease). Angiology 57, 73-78, (2006).
• Cacione, D. G., Macedo, C. R. & Baptista-Silva, J. C. C. Pharmacological treatment for Buerger's disease. Cochrane Database of Systematic Reviews (2016).
• Klein-Weigel P, V. T., Zange L, Richter J. Buerger’s disease: providing integrated care. Journal of Multidisciplinary Healthcare 9, 511-518 (2016).

Critical Limb Ischemia (Peripheral Artery Disease)

• Armstrong, E. J. et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. Journal of Vascular Surgery 60, 1565-1571 (2014).
• Farber, A. & Eberhardt, R. T. The current state of critical limb ischemia: A systematic review. JAMA Surgery 151, 1070-1077, doi:10.1001/jamasurg.2016.2018 (2016).
• Alonso, A. and Garcia, L. The Costs of Critical Limb Ischemia: Patient prognoses and the economic impact of CLI on vascular practices and the national health care system. Endovascular Today, 32-36 (2011).
• Novo, S., Coppola, G. & Milio, G. Critical Limb Ischemia: Definition and Natural History. Current Drug Targets - Cardiovascular & Hematological Disorders 4, 219-225(2004).
• O'Brien-Irr, M. S., Dosluoglu, H. H., Harris, L. M. & Dryjski, M. L. Outcomes after endovascular intervention for chronic critical limb ischemia. Journal of Vascular Surgery 53, 1575-1581 (2011).
• Lu, L., Mackay, D. F. & Pell, J. P. Meta-analysis of the association between cigarette smoking and peripheral arterial disease. Heart 100, 414-423, doi:10.1136/heartjnl-2013-304082 (2014).

Smoking Cessation Pharmacotherapies

• Cahill, K., Stevens, S., Perera, R. & Lancaster, T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database of Systematic Reviews (2013).
• Fiore MC, J. e. C., Baker TB, et al. Treating tobacco use and dependence: 2008 update. (ed HHS) (Public Health Service, Rockville, MD, 2008).
• Gonzales, D. et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296, 47-55 (2006).
• Jorenby, D. et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296, 56-63 (2006).

Nicotine and Addiction

• Benowitz, N. L., Hukkanen, J. & Jacob, P., 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handbook of experimental pharmacology, 29-60 (2009).
• Volkow, N. D., Koob, G. F. & McLellan, A. T. Neurobiologic Advances from the Brain Disease Model of Addiction. New England Journal of Medicine 374, 363-371(2016).
• The Tobacco Atlas, American Cancer Society and Vital Strategies (2018)
• USHHS. The Health Consequences of Smoking—50 Years of Progress, A Report of the Surgeon General (2014).